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Each step of the cell life and its response or adaptation to its environment are mediated
by a network of protein/protein interactions termed “interactome.” Our knowledge of this
network keeps growing due to the development of sensitive techniques devoted to study
these interactions.The bioluminescence resonance energy transfer (BRET) technique was
primarily developed to allow the dynamic monitoring of protein/protein interactions (PPI)
in living cells, and has widely been used to study receptor activation by intra- or extra-
molecular conformational changes within receptors and activated complexes in mammal
cells. Some interactions are described as crucial in human pathological processes, and a
new class of drugs targeting them has recently emerged.The BRET method is well suited
to identify inhibitors of PPI and here is described why and how to set up and optimize a high
throughput screening assay based on BRET to search for such inhibitory compounds. The
different parameters to take into account when developing such BRET assays in mammal
cells are reviewed to give general guidelines: considerations on the targeted interaction,
choice of BRET version, inducibility of the interaction, kinetic of the monitored interaction,
and of the BRET reading, influence of substrate concentration, number of cells and medium
composition used on the Z ′ factor, and expected interferences from colored or fluorescent
compounds.
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INTRODUCTION
Protein/protein interactions (PPI) govern all key events in a cell
life, from division, to adaption or response to extracellular sig-
nals leading to biological effects. However, this view was not
so obvious in the past, as convincing examples demonstrating
such phenomena were exceptional and hard to achieve. In the
last decade, numerous methods with increasing sensitivities and
potencies have been developed, allowing the monitoring of those
interactions (Xu et al., 1999; Tavernier et al., 2002; Chan, 2004;
Brovko and Griffiths, 2007; Michnick et al., 2007; Ventura, 2011;
Hamdi and Colas, 2012). Evolution of such methods has allowed
the dynamic detection of PPI in living cells (Xu et al., 1999; Coulon
et al., 2008; Lee et al., 2010; Quiñones et al., 2012) and nowadays
in whole living organisms (Subramanian et al., 2004; Audet et al.,
2010). Following this evolution scheme, PPI pathways have been
deciphered and furthermore organized in higher protein networks
ranging from PPI taking place in molecular complexes, to entire
organelles and to whole organisms (Coulon et al., 2008; Chautard
et al., 2009; Jaeger and Aloy, 2012). Our current knowledge of these
PPI networks has further increased in recent years with the emerg-
ing idea that more than PPI networks themselves, the biological
context in which they occur is important. System wide analyses of
PPI crossing genetic data or pathological states of the cells from
which they were generated have been performed and led to new
data pointing out the changes in PPI networks in some human
pathology (Bader et al., 2008). Deciphering that a fine PPI change
can lead to a drastic PPI network modification was the bases of
a pathological state, has opened new views for drug discovery.
Applying this concept by using the current knowledge of protein
interaction network modification in glioblastoma cancer cells, a
recent study allowed the successful screening of inhibitory peptide
disrupting PIKE-A/Akt and their capacity to inhibit the prolifer-
ation of these cells (Qi et al., 2012). Attempts to gain exhaustive
interactome taking place in diseases have became common. These
growing data demonstrate that most proteins interact with more
than one partner (Krause et al., 2004) and lead to better drug
target choosing. Indeed the deciphering of deregulated or key
interactions in diseases crossed with interactions involved in the
less pathways allows to minimize or avoid unexpected side effects
(Chen et al., 2012).
To search for inhibitors of PPI, the same methods used to
detect the interactions can be used. The need for robust and high
throughput screening (HTS) compatible method, when perform-
ing screening assays, has lead to the preferential use of techniques
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such as yeast two hybrid and derivatives (Hamdi and Colas, 2012),
Fluorescence polarization (Smith and Eremin, 2008), MAPPIT
(Lievens et al., 2011); and protein complementation assay (Morell
et al., 2009; Michelini et al., 2010). Other methods based on
resonance energy transfer (RET) to monitor PPI, offers great
advantages as they allow full length proteins dynamic interaction
monitoring in intact cellular contexts and are applicable to HTS
(De, 2011). In this review, the use of RET and more advanta-
geously PPI inhibitors (P2I2) bioluminescence resonance energy
transfer (BRET)-based screening assays in mammalian cells will
be developed.
THE DIFFERENT RET METHODS
To date, three main RET methods have been developed and used in
drug screening assays: FRET (Forster Resonance Energy transfer),
BRET and HTRF (Homogeneous Time Resolved fluorescence).
All RET methods are based on the use of compatible energy donor
and acceptor couples allowing RET to take place when donor and
acceptor are in close proximity (<10 nm). To be a compatible
couple, the energy donor emission wavelength has to overlap the
energy acceptor excitation one in order to gain energy transfer
(Figure 1A). The energy donor and acceptor are each linked to
one of the interacting partners and resonance can occur if the
two partners interact and close the donor and acceptor by a dis-
tance less than 10 nm. In the FRET method (Figure 1B), donor
and acceptor are both fluorophores and a proper excitatory light
is needed to promote donor emission (Fruhwirth et al., 2011). In
FRET cellular screening assays, donor and acceptor are two flu-
orescent proteins each genetically fused to one of the interacting
partners. In the BRET method (Figure 1C), the energy donor is a
bioluminescent enzyme, converting its substrate into light emis-
sion able to promote RET with a compatible fluorescent acceptor
(Pfleger and Eidne, 2006; Bacart et al., 2008). For live cell screen-
ing purpose, BRET assays involve genetically engineered fusion
protein of the studied partners respectively with the donor and
acceptor. HTRF is an enhanced FRET derivative method which
circumvents the major FRET problem due to simultaneous excita-
tion of acceptor by donor excitatory light. This method is based on
energy transfer monitoring in a time resolved manner (Degorce
et al., 2009). Indeed the donor used is a fluorescent molecule able to
emit light for a short time period after the excitatory light has been
turned off (Figure 1D). This last property allows the monitoring
of energy transfer to a compatible acceptor once the excitatory
light is switched off.
All these RET methods have several advantages over the other
methods to monitor PPI, that make them the best suited method
to detect PPI in mammalian cells. FRET, HTRF, and BRET are
homogenous assays as the energy transfer signal is only emitted
from the interacting partners, and then, no artifact prone washing
steps are required before reading. Each of these methods has its
advantages and limits that make them best suited methods in cer-
tain fields. In P2I2 live cell screening assays BRET present several
advantages over other RET methods.
WHY CHOOSING BRET TO SCREEN FOR PPI INHIBITORS?
Classical FRET and BRET screening assays have a subsequent
advantage over HTRF as they mostly rely on genetically fused
FIGURE 1 | Resonance energy transfer methods. (A) Basic properties of
donor/acceptor compatible couple in order to gain RET. Principles of (B): the
FRET method, (C): The BRET method, and (D): the HTRF method. D, Donor;
A, Acceptor; S, Substrate.
energy donor and acceptor proteins respectively to both partners
implicated in the monitored interaction. Using such fusion pro-
teins can however be a disadvantage as fusion can promote steric
hindrance hindering wild type interactions. On the other hand,
HTRF is able to monitor unmodified protein interactions but
involves a latter step of protein labeling with antibodies or chemical
linkage (Degorce et al., 2009) which lower its interest in live
cell P2I2 HTS assays. BRET shows several advantages over FRET
(Boute et al., 2002): first, the excitation of the donor fluorophore by
monochromatic light in FRET also lead to the concomitant exci-
tation of the acceptor then hardening the results interpretation;
second, this excitatory light promote photobleaching of the donor
and cell autofluorescence; and third, BRET signal/noise ratio has
been shown to be 10-fold higher than FRET thus allowing the use
of 40-fold less amount of protein to reach the same signal level
than FRET (Arai et al., 2001). This last parameter is important
for screening P2I2 as over-expression of proteins (excess of the
monitored complex) might titer a potential active molecule lead-
ing to its inability to promote the expected decreased in signal.
Indeed, BRET superiority was shown by its ability to monitor PPI
using endogenous level of protein expression (Couturier and Jock-
ers, 2003; Pfleger and Eidne, 2003) and its consequent application
to various live cell screening assays (Pfleger et al., 2007; Bacart
et al., 2008; Kocan and Pfleger, 2011). Finally, using this method to
screen for P2I2 is further supported as BRET is prone to disruption
Frontiers in Endocrinology | Molecular and Structural Endocrinology September 2012 | Volume 3 | Article 100 | 2
Couturier and Deprez P2I2 BRET-based screening assay setup
or modulation by co-expression of untagged interacting partner
(Bacart et al., 2008; Ayoub and Pfleger, 2010; Kulahin et al., 2011)
and by incubation with inhibitory peptides (Granier et al., 2004;
Harikumar et al., 2006; Jarry et al., 2010) or inhibitory chemical
compounds (Mazars and Fåhraeus, 2010; Corbel et al., 2011).
FOR WHICH KIND OF TARGET INTERACTION CAN THE BRET
BE CHOSEN?
The BRET method has already been applied to monitor interaction
between various kinds of proteins partners and in various cellular
components (Bacart et al., 2008; Alvarez-Curto et al., 2010). This
range from two soluble proteins, two transmembraneous ones,
one transmembraneous, and one soluble, with interactions taking
place in cytoplasm, nucleus, and cytoplasmic or internal mem-
branes (Coulon et al., 2008; Guan et al., 2009; Bacart et al., 2010).
Indeed BRET is able to monitor all kinds of interaction, however,
certain concerns have to be taken into account when designing
P2I2 BRET-based assays. First, the BRET signal is dependent on the
donor/acceptor ratio as described by the well-known donor satu-
ration assay (DSA; Mercier et al., 2002; Bacart et al., 2008; Ayoub
and Pfleger,2010; Figure 2A). The DSA leaded to further analyze of
the BRET signal and demonstrated that the maximal BRET inten-
sity is dependent on the ratio of energy donor interacting with an
energy acceptor versus free energy donor present in the cell (Cou-
turier and Jockers, 2003; Ayoub et al., 2004; Figure 2B). Indeed
at equimolar ratio, if all donors and acceptors molecules inter-
act together, a maximal BRET would be raised. However, this is
rarely the case and free donors molecules (or interacting with other
but non-acceptor-tagged proteins) lead to decrease this maximal
BRET value. Given that, in order to gain the higher BRET signal,
the acceptor fusion protein would be highly expressed compared
to the energy donor to lower the free donor proportion. However,
to ensure the monitoring of active compounds effects, the titration
of the compound by excess acceptor has to be avoided. In order to
prevent this phenomenon, the level of expression of both partners
would result in an ideal window leading to high BRET signal still
located in the dynamic range of DSA curves (Figure 2C).
Furthermore, this last parameter will guide the choice for the
design of the fusion proteins. As the proportion of free donor will
lead to decrease the BRET signal, it has to be the lowest and the
choice to fuse it to a X or Y protein will be the global ratio of
X /Y complexes versus X or Y that are free or engaged in other
complexes than the one studied.
Bioluminescence resonance energy transfer is also well suited to
monitor transitory interaction but with the same restriction: when
performing the reading, the BRET signal will depend on the per-
centage of donor/acceptor complexes versus the donor alone and
would be hard to monitor if this percentage is low. Some modifica-
tions can enhance the monitoring of such interaction like substrate
trapping strategy that disables the substrate/enzyme dissociation
(Boute et al., 2003; Issad et al., 2005; Boubekeur et al., 2011).
WHICH BRET VERSION TO CHOSE?
To screen for P2I2, compound titration by excess reporter amount
has to be avoided. For in vitro interaction methods, setting up
the protein quantities to use is easily done, however this is harder
to achieve for live mammalian cell BRET-based assays. Indeed,
FIGURE 2 | Bioluminescence resonance energy transfer donor
saturation assay. (A) Basic donor saturation assay expressed as milliBRET
unit (mBU); (B) Donor Saturation Analysis for dimeric complexes formation:
in red, theoretical curve if 100% donor and acceptor interact with each
other at a 1/1 molar ratio. In blue, the common DSA curves obtained
showing lower percentage of donor/acceptor complexes in cells. (C) Donor
saturation assay for analysis to set up a P2I2 BRET-based screening assay.
In hatched black, the dynamic windows of BRET monitoring. In hatched red,
the two areas of the DSA curve to avoid. In green, the ideal window to be
chosen when setting up a P2I2 BRET-based screening assay.
choosing the most sensible and most compatible with HTS over the
different BRET versions available seems to be the only way to gain
the necessary highest readout. This choice became difficult nowa-
days as several BRET methods based on different substrates and
different compatibles donor/acceptor couples have been developed
(Bacart et al., 2008; De et al., 2009; Lohse et al., 2012).
BRET1
Original BRET1-based on the Rluc/YFP couple showed low signal
(Xu et al., 1999) hindering its use in HTS. Higher signals were
obtained using mutants or new cloned acceptors such as YFP
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Topaz, YFP citrine, YFP Venus, YPet, or the Renilla-GFP (R-GFP;
Bacart et al., 2008; Molinari et al., 2008; Kamal et al., 2009; Ayoub
and Pfleger, 2010). YFP Venus was used to demonstrate the feasi-
bility of a BRET1 HTS assay in CCR5 ligands screening (Hamdan
et al., 2005). The BRET1 readout signal was also enhanced by the
concomitant use of these acceptors with mutants of Rluc or other
luciferases. Rluc2 or Rluc8, mutants of Rluc with higher stability
and quantum yield (Loening et al., 2006), greatly increased BRET1
signal (Kocan et al., 2008; Kamal et al., 2009; Schelshorn et al.,
2012). Recently, BRET1 was used to develop two P2I2 screening
assays (Mazars and Fåhraeus, 2010; Corbel et al., 2011).
BRET1 has also been achieved using Gaussia Luciferase (Gluc).
Gluc is a smaller and brighter luciferase known to date and was
cloned from a marine copepod (Tannous et al., 2005; Welsh et al.,
2009). It shares some spectral properties with Rluc and has been
recently used in BRET1 assays (Li et al., 2012).
BRET1 method using quantum dot (Qdot) as energy accep-
tors has also been reported these past few years. These photostable
fluorescent nanoparticles are excitable at 480 nm and have a size
dependent emission wavelength tunable to the overall rainbow
colors (Weng and Ren, 2006). Qdot BRET-based assay have first
shown energy transfer efficiency (So et al., 2006) and in vitro pro-
tease assays have been later developed (Xia et al., 2008; Kim and
Kim, 2012). However, the coupling to proteins (Algar et al., 2010)
and the cellular toxicity (Soenen et al., 2012) of Qdot are still an
obstacle to their use in live mammalian cell for PPI monitoring.
BRET2
Bioluminescence resonance energy transfer 2 method was devel-
oped by Packard Biosciences by increasing the separation of the
two emitted wavelength to circumvent the poor signal/noise ratio
of BRET1. This enhancement relies on the concomitant use of
coelenterazine 400a (or deep blue C), a coelenterazine derivative
that forces the Rluc emission to a 397 nm peak, and the compatible
energy acceptor GFP2 (a mutant of aequorea GFP; Ramsay et al.,
2002). BRET2 has been successfully used for ligands screening
(Vrecl et al., 2004; Elster et al., 2007), and virus protease inhibitors
screening (Hu et al., 2005; Oka et al., 2011). However, BRET2
has suffered from a weak and short lasting light emission that
greatly limited its use to develop P2I2 BRET-based HTS assays.
Indeed, high expression of BRET partners is necessary to ensure
signal recording. BRET2-based PPI assay using Rluc2 or Rluc8
have shown enhanced BRET dynamic range and kinetic of the
reading up to 1 h (De et al., 2007; Kocan et al., 2008; Dacres et al.,
2009, 2012; Kulahin et al., 2012). However, BRET2 has not been
used in P2I2 screening assays yet and its use in this field would still
need to be demonstrated.
BRET3
A BRET3 method using firefly luciferase (Fluc) and dsRed or
Cy3 as compatible acceptor has been developed (Arai et al.,
2002; Yamakawa et al., 2002). However, the huge overlap of
donor/acceptor emission peaks of this method leads to extremely
low signal to noise ratio that impaired its application to really study
protein/protein interactions. A better proof of concept was gained
by the use of mOrange as acceptor that allowed PPI monitoring in
live cells and animals (De et al., 2009). More recently, new analogs
of luciferin (the firefly substrate), leading to different spectral
properties of the emitted light, were synthesized and showed their
efficiency in BRET3 experiments (Takakura et al., 2010, 2011).
One of these, coumarylaminoluciferin allowed a mutant of Fluc
to emit light compatible with the use of YFP as acceptor (Takakura
et al., 2010) and may promote advances of the BRET3 version by
using the various YFP variants developed for BRET1. At this stage
of development, BRET3 has not been yet demonstrated to be a
valuable method to screen for P2I2.
FUTURE BRET ENHANCEMENTS
Although major advances have already been made since the 1999s
BRET version, further improvements of BRET methods are still
expected. As described above, the BRET enhancements were based
on the use of variants of luciferases or fluorescent acceptors, cou-
pled to the concomitant use of modified substrates. New improve-
ment of know luciferases are on the way and would probably lead
to new BRET advances. A systematic pairing of luciferases with
compatible substrates have highlighted best couples: Rluc/enduren
and Gluc/native coelenterazine h are 8- to 15-folds brighter than
the princeps BRET1 (Kimura et al., 2010). Another study sorted
mutants of Gluc with a up to sixfold enhancement in light emis-
sion and a 10-fold prolonged bioluminescence than native Gluc
which was already the brighter luciferase (Kim et al., 2011). Vargula
luciferase (Vluc) shares quite the same spectral properties than
Rluc and has been applied to BRET1 (Otsuji et al., 2004). Metridia
pacifica luciferase 1 (MPluc1) and Metridia longa luciferase (Mluc)
or its mutants emits in the 450–500 nm range and have thus poten-
tial to be used in BRET assays in the future (Takenaka et al., 2008;
Kim et al., 2011; Markova et al., 2012). Recently, Nanoluc™, a
new deep-sea shrimp evolved luciferase has been introduced by
Promega (Hall et al., 2012). This 171 amino acids (19 kDa) ATP
independent glow-type luciferase using furimazine as substrate is
announced to have more than 100-fold higher luciferase activity
than Rluc or FLuc. Its maximal emission peak at 465 nm makes
it compatible with current BRET acceptors and its efficient appli-
cation in two BRET-based assays has furthermore been shown.
Its high activity allows lowering Donor amount needed to ensure
sufficient BRET signal and may thus enhance the sensitivity of the
method.
BRET1 OR BRET2?
Due to recent advances, the proper choice between BRET1 and
2 versions became difficult. Due to the lack of studies systemati-
cally comparing each BRET enhanced methods with each other, a
ranking of the BRET signal and the amount of protein needed
to reach it is hard to achieve. Both methods recently reached
higher sensitivity, readout, and kinetics parameters that render
them fully compatible with HTS. However, BRET1 basic method
has been shown to be able to monitor PPI at endogenous expres-
sion level of proteins (Couturier and Jockers, 2003; Pfleger and
Eidne, 2003) thus allowing the use of lower protein expression
level than BRET2 in order to avoid active compound titration.
Furthermore, Rluc and Rluc 8 as energy donor were systematically
tested in BRET1 and BRET2 identical assays and showed the bet-
ter sensitivity of BRET1 over BRET2 in living cells (Kocan et al.,
2008). However, another study found the opposite (Dacres et al.,
2009). To date, only BRET1-based P2I2 screening assays have been
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described and showed the feasibility of this approach (Mazars and
Fåhraeus, 2010; Corbel et al., 2011). BRET1 seems to be nowadays
the best suited BRET method to develop P2I2 screening assays
until proven otherwise.
HOW TO SET UP A BRET ASSAY TO SCREEN FOR PPI
INHIBITORS?
VALIDATION OF THE SPECIFICITY OF THE INTERACTION
The BRET signal is dependant on the ratio of donor/acceptor as
it has been shown for years, using the well-known DSA, to show
the specificity of the interaction. The first step to screen for P2I2
using BRET in cells is to verify this point by performing DSA
experiments or other characterization such as untagged competi-
tor protein cotransfection or effect of a known ligand promoting
change of the BRET signal (Bacart et al., 2008; Ayoub and Pfleger,
2010).
PRODUCTION OF INDUCIBLE BRET CELL LINES
In order to set up a screening assay, the BRET signal has to be high,
reproducible and stable, however, as revealed by DSA, fine changes
in the donor or acceptor expression in transitory transfections will
lead to a change in the BRET signal (Figure 2A). To ensure the sta-
bility and reproducibility of the signal needed for a screening assay,
cell clones stably expressing the donor alone (Control cell line) and
the donor/acceptor couple (BRET cell line) would be prepared as
this was done for most BRET-based screening assays. Disrupting
a PPI might be hard or quite worthy to achieve, this is why P2I2
screening assays developed until now were designed in vitro to
allow compound tested to inhibit interaction before it takes place.
For BRET-based assay, it is easily achieved if the studied inter-
action is naturally induced such as promoted receptor/effectors
interaction upon ligand addition (Kamal et al., 2009; See et al.,
2011). However, for constitutive interactions, designing such suc-
cessful assays in living cell using BRET implies the use of a fast
inducible system to add the chemical compound before inducing
the target interaction (Corbel et al., 2011). Several mammalian
tight inducible systems have been developed to reach this goal
(Clackson, 1997). However, for screening protocol conveniences;
repressed gene expression systems overcame by inducer molecule
represents the best strategy. Several inducible systems are based
on this scheme: Tet-on systems, based on a tet repressor (TetR)
binding to tet operator elements of a promoter and displaced by
addition of tetracycline derivatives thus allowing the target gene
expression (Shockett and Schatz, 1996; Sun et al., 2007); Ecdysone
systems and derivatives, based on glucocorticoids promoted asso-
ciation of an active steroid hormone nuclear receptor enabling
expression of a target promoter (No et al., 1996; Xiao et al., 2003),
and Q-mate™ based on a steric hindrance due to cumate repres-
sor protein CymR bound to operator sites on the target promoter
and which is released by addition of the inducer molecule cumate
(Mullick et al., 2006). Two cell lines have to be developed to allow
subtraction of the background BRET signal (from control cell line)
from the interaction promoted BRET signal (BRET cell line). In
order to gain comparable background luciferase activity in both
cell lines, the BRET cell line would be advantageously prepared
by introducing the acceptor tagged protein in the genome of the
control cell line.
WHICH BRET PARTNER TO INDUCE?
Given the DSA curves, the maximal BRET signal is achieved when
the donor is saturated by the acceptor. The resulting strategy would
then be to express this one constitutively and the donor-fused
partner in an inducible way. This kind of inverse DSA would lead
to a high BRET signal tending to its maximal value as soon as the
donor expression is induced. To ensure this ideal scenario, several
parameters have to be taken into account when selecting the cel-
lular clones. First of all, a low background expression of the donor
is needed; otherwise a high BRET signal would be readily present
before induction. Second, a sufficient acceptor expression has to be
reached to ensure high maximal BRET values but low enough to
avoid titration of compounds targeting this moiety. Third, dur-
ing the induction process, the molecular amount of expressed
donor would not exceed the one of the acceptor as the BRET signal
would then decrease by free donor accumulation. Another impor-
tant point to take into account is the location of the monitored
interaction. Constitutively expressed acceptor would have reached
its proper location whereas, upon induction, the donor will be
neo-synthesized and a delay is then expected for it to reach final
location and interact with its partners. The BRET signal appear-
ance is then expected to be delayed, however, unless compound
modify translation rate or transit through/between cellular com-
partments, this delay would be the same in presence or absence of
screened compound incubation when verifying primary hits.
HOW TO OPTIMIZE A P2I2 BRET-BASED ASSAY?
When setting up a primary screening assay, efforts have to be made
to make it easy, fast, highly reproducible, and to lower the associ-
ated costs. To this aim, several parameters described below can be
optimized when setting up P2I2 BRET-based screening assays to
assume these efforts.
FAST AND EASY PROTOCOL
The use of an inducible and stably expressing cell clones seems to
be a prerequisite to ensure ease and reproducibility of such P2I2
BRET-based screening assays. An example using transitory trans-
fection has shown that a known inhibitory compound was active
in this assay (Mazars and Fåhraeus, 2010), however no hits based
on this assay has been further published. On the contrary, a suc-
cessful P2I2 screening assay using yeast stably expressing donor
and acceptor respectively in an inducible and constitutive way has
led to identification of chemical hits able to prevent the interac-
tion between human cdk5 and p25 (Corbel et al., 2011). This study
showed for the first time a real success for such P2I2 BRET-based
screening assays. In order to keep the homogeneity of the test,
efforts to set up a protocol avoiding unnecessary washing steps
would be done. This can be achieved by some typical protocol as
shown on Figure 3A: cells are first dispatched in wells, allowed to
adhere, and rinsed (or not) to lower background donor expression.
After this last step, addition of medium, compounds, inducer of
the donor expression, and finally the donor substrate to perform
the reading are then chronologically added.
KINETIC OF THE MONITORED INTERACTION
The use of an inducible system to ensure compound inhibitory
action before the interaction takes place also lead to the prob-
lem of the kinetic of the studied interaction after induction. In
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FIGURE 3 | Setting up and optimize a P2I2 BRET-based screening
assay. (A) Basic protocol of P2I2 BRET-based screening assay; (B–H)
parameters analysis of the BRET signal monitored using
OBRc/OBRGRP (•) and CD4/PLSCR1 (◦) BRET-based screening
assays, engineered using CHO-Trex cell lines to allow doxycyclin
induction of donor. n=3; (B) kinetic of the BRET induction: BRET signal
monitored as a function of time after inducer addition (doxycyclin
0.1µg/ml). (C) Kinetic of the BRET reading after coelenterazine h
addition and (D) effect on the Z′ factor calculated from 8 points. n=3.
(E) Effect of substrate concentration or cell number used (F) on the Z′
factor (from 8 points). n=3; (G) dose dependent effect of red phenol or
Fluorescein (H) interfering compound in the medium when reading
BRET. In gray when medium was removed before reading:
OBRc/OBRGRP (•) and CD4/PLSCR1 (◦).
order to know the maximal BRET value reachable as a function of
induction time, a kinetic of the induction would be performed for
each inducible P2I2 BRET-based assay developed. To show the fea-
sibility of such an inducible BRET approach in mammalian cells,
two cellular (tet-on based) inducible P2I2 BRET-based assays were
developed to monitor the kinetic of the induction. The first test was
based on a previous BRET demonstration that interaction of the
leptin receptor (OBR) with OB-RGRP negatively regulated OBR
expression at the cell surface and was implicated in leptin resistance
(Couturier et al., 2007). The second, monitoring the interaction
between CD4 and phospholipid scramblase 1 (PLSCR1) was devel-
oped, based on finding showing that disrupting this interaction
may inhibit HIV entry into cells (Py et al., 2009). As seen on
Figure 3B, a maximal BRET value was reached after 24–48 h of
induction by doxycyclin for both assays and BRET signal was very
stable. In order to shorten the screening campaign,a 24 h induction
time would be chosen in the present cases.
KINETIC OF THE BRET READING
When reading BRET, the kinetic of the Rluc emission is a cru-
cial point as the BRET ratio is known to be stable only when
it decreases. Depending of the temperature, the level of protein
expressed, and of the developed test, the time to reach the decreas-
ing activity step of the Rluc may vary from seconds to 5–15 min.
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The proper kinetic has then to be determined for each developed
BRET assay and a corresponding delay has to be added in the
process before reading. Another crucial point when performing a
screening assay is the emitted light that have to last long enough
to ensure at least the reading of an entire 96 or even 384 wells
plate. However, it is well-known that the Rluc activity and per se
the BRET signal cannot be monitored for a long time period. To
date some BRET kinetic experiments have shown reliable signal
for at least 30–60 min using coelenterazine h (Kocan et al., 2008;
Matthiesen and Nielsen, 2011).
To circumvent the short lasting period of the Rluc emission and
increase its light output, efforts have been made to develop some
new substrates for BRET 2 or BRET 1 (Zhao et al., 2004). Two
BRET1 compatible substrates have been produced by Promega
to gain better kinetics parameters for Rluc in vivo and in live
cells (ViViren and Enduren respectively). These substrates have
protected oxidation sites to lower the autoluminescence due to
their degradation and are metabolized to coelenterazine h by cel-
lular esterases. The light output superiority over coelenterazine
h has been shown for both these substrates (Otto-Duessel et al.,
2006; Kimura et al., 2010), and the interest of using enduren was
confirmed by studies showing maintained luciferase activity and
BRET1 signal for up to 9 h (Dinh et al., 2005; Pfleger et al., 2006).
However, the expensive cost of such substrates may explain their
restricted use and hinder their application in BRET-based assay
screening campaigns.
Using both our cellular inducible P2I2 BRET-based assays,
we tested the kinetic of the BRET reading using common ceo-
lenterazine h. Unexpectedly the BRET ratio remained reliable
for as long as 3 h after substrate addition (Figure 3C) how-
ever, the Z ′ value was compatible with screening (>0.5) for
at least 80 min (Figure 3D). BRET monitored using coelenter-
azine h substrate is then sensitive enough and finally sufficiently
long lasting to allow the automated addition of substrate in sev-
eral plate and their reading over an extended time period using
stackers.
INFLUENCE OF SUBSTRATE CONCENTRATION
The cost of a screening assay is a question of matter and regard-
less the price of compounds collection to be tested, a BRET-based
assay includes the cost for the necessary substrate for each well
to be read. To lower this cost, the total volume incubated in the
wells has to be as low as possible to add the lower amount of sub-
strate to reach the proper final concentration. Since the princeps
publication describing BRET1 and until now, most BRET-based
screening assays mostly used coelenterazine h at a final concen-
tration of 5µM (Boute et al., 2001; Charest et al., 2005; Hamdan
et al., 2005; Laursen and Oxvig, 2005; Pfleger et al., 2006; Percher-
ancier et al., 2009; Corbel et al., 2011; Kang et al., 2011) or even
up to 30µM (Vizoso Pinto et al., 2011). In order to monitor the
effect of lowering the concentration of substrate on the BRET
ratio and the Z ′ parameter, both our P2I2 BRET-based assays
were used. As shown on Figure 3E, the Z ′ factor remain higher
than 0.5 for a concentration of 1µM and even 0.5µM however it
comes closer to the limit of 0.5. A final concentration of 1µM can
then be safely used when performing a P2I2 BRET-based screening
campaign.
INFLUENCE OF THE NUMBER OF CELLS
When performing P2I2 screening assay, efforts have to be done to
lower the amount of targeted complex to avoid or at least lower
titration of the tested compound to gain high sensibility. The easy
way to do it is to lower the number of plated cells, but the signal has
to be still reliable and reproducible. To test this we plated varying
number of cell from both our P2I2 assays we developed in 96 wells
plate format and calculated the Z ′ factor from the BRET results.
As can be seen on the Figure 3F, the Z ′ factor remains compatible
with screening using lower cell number than 5000 but closest the
0.5 limit. 5000–10000 cells might then be used when performing
such assay to ensure proper reliability.
INFLUENCE OF THE BRET READING BUFFER ASSAY
To perform a BRET assay in live cell, one would keep the cells in
an as physiological context as possible and then perform the full
experimental protocol from compound incubation to reading in
proper cell culture medium. This is done currently in most stud-
ies, except for the final reading step which is mostly performed by
replacing the medium with PBS containing the proper BRET sub-
strate (See et al., 2011) or phenol red free medium. Indeed, when
performing the BRET reading using medium containing red phe-
nol, a shift in the BRET ratios is expected (Figure 3G), probably
due to a change of the properties of the donor and/or the accep-
tor emissions or simply a physical change in the propagation of
the light waves in the medium. Until recently, no dedicated study
was done to monitor the effect of the reading buffer assay. Using a
hGluc-(enterokinase cleavage site:-EYFP fusion, it has been shown
that current buffers used to perform BRET reading such as Tris,
Tricine, Sodium, HEPES, or MOPS are not the best to choose
(Li et al., 2012). This study also showed that pH change of the
medium promoted a change in the BRET signal (with a maxi-
mal value at ph 9), and furthermore that divalent cations such as
Mg2+ and Ca2+ promoted a decrease in the BRET ratios. Most
importantly, they have shown that adding imidazole to the reading
medium promoted a 10-fold increase in the sensitivity of the assay
and a sevenfold increase of the detection limit of the enterokinase
activity. Although this was done using hGluc as donor, this study
opens the way to monitor these parameters for other donors, as the
monitored effects were not due to a drastic change in the luciferase
activity but rather a change in the transfer efficiency. Future studies
would find enhanced BRET buffers for BRET1 and BRET2 assays,
in regards to the donor and acceptor used.
INFLUENCE OF COLORED AND FLUORESCENT COMPOUNDS
As describe in the previous paragraph, the BRET signal can be
modulated by the composition of the medium in which the reading
is performed. Interfering compounds used in the reading buffer,
on both control and BRET cell lines of a P2I2 BRET-based assay,
would not be such a problem as the effect would be present in all
wells measured leading to an overall increase or decrease of the sig-
nal. However, when performing a compound screening assay, if a
compound in a particular well lead to such a change, a false positive
or negative signal would be expected, as this well is compared to
controls incubated with vehicle only. As shown using red phenol
versus red phenol free medium (Figure 3G) a BRET decrease is
monitored. A colored compound having such properties would
www.frontiersin.org September 2012 | Volume 3 | Article 100 | 7
Couturier and Deprez P2I2 BRET-based screening assay setup
be expected to lower the BRET signal due to a change in the
medium properties, but not to a decrease in the studied inter-
action. On the other hand, fluorescent compounds sharing the
same spectral properties than the acceptor, would also promote
a change in the BRET signal, due to a saturation of the read-
ing medium. A donor saturation effect leading to a BRET change
would be expected by the free concentrated fluorescent compound
if the donor emitted light overlaps the excitation one of this com-
pound. In the case that the emission wavelength of the fluorescent
compound is close to the acceptor emission, an artifactual BRET
enhancement would be expected. Indeed, by incubating increasing
concentration of Fluorescein on both our BRET screening assays,
a huge BRET increase was monitored in a dose response man-
ner. However, by replacing the medium containing Fluorescein by
PBS before reading, the same BRET modulation was shown to be
decreased by a 2 order dilution (Figure 3H) indicating that this
effect was mostly mediated by the simple presence of Fluorescein
in the medium. Therefore, when performing a P2I2 BRET-based
screening assay, the reading of the fluorescence is necessary to
exclude or to evidence those artifacts.
WHAT ARE THE EXPECTED RESULTS?
If a molecule inhibits the studied interaction, a decrease in BRET
signal is expected (Figure 4A). The BRET method is a well suited
method for this purpose as the signal relies on the ratio of the two
emitted wavelengths (respectively from the donor and the accep-
tor). The BRET intensity is then dependent of the percentage of
interacting partners in the cell (Figure 2A). A PPI inhibitory com-
pound is then expected to reduce the amount of the BRET inter-
acting partners as well as increasing the non-interacting donor
proportion, leading to an enhanced BRET signal decrease, higher
than just decreasing the interacting partner amount. Such P2I2
screening using energy transfer methods, might then lead to lower
the IC50 values, and therefore to enhance the detection limit of
such active compound when using a given concentration.
As the energy transfer is dependent of the distance between
donor and acceptor but also the relative orientation of their
dipole moment (Stryer and Haugland, 1967; Hickerson et al.,
2005; Majumdar et al., 2005), RET methods allows to monitor
the presence of the targeted interaction as well as fast confor-
mational changes in the studied complex (Vilardaga et al., 2003;
Milligan, 2004; Lohse et al., 2008; Alvarez-Curto et al., 2010).
Such conformational changes, prone to promote a RET signal
change (increase or decrease), lead to expect a higher hit rate
than other PPI monitoring methods. Hence, such conformational
modulators are unable to be detected using classical methods basi-
cally monitoring the presence of the interaction, unless they also
promote a dissociation of the targeted complex.
Among RET methods, BRET has been shown to allow the
monitoring of intramolecular or intermolecular conformational
changes with high sensitivity and even only tiny changes due to
point mutations (Milligan, 2004; Bacart et al., 2008; Alvarez-Curto
et al., 2010; Darbandi-Tehrani et al., 2010). P2I2 BRET-based
screening assays might then detect interactions inhibitors but
also conformational modulators (Figure 4A) that do not promote
interaction disruption but might lead to a change in the biological
function as well. BRET experiments have been successfully used
FIGURE 4 | Expected results from a P2I2 BRET-based screening assay.
(A) Different expected BRET change upon inhibitor or modulator compound
action compared to basal BRET signal. X andY : Protein X andY ; D: energy
donor; A: energy Acceptor; S: BRET Substrate. (B) Results of a 320
compounds miniscreen using OBRc/OBRGRP (•) and CD4/PLSCR1 (◦)
BRET-based screening assays, expressed as% of basal BRET in absence of
compound in each plate. (C) Fluorescence measured from the same plates
as in (B) expressed as % of fluorescence value in absence of compound
(represented by•).
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to show ligands promoted conformational changes of receptors
upon binding and leading to biological effects (Boute et al., 2001;
Ayoub et al., 2002; Couturier and Jockers, 2003; Blanquart et al.,
2006; Galés et al., 2006; Audet and Piñeyro, 2011). However, no
systematic correlation between BRET increase or decrease and the
biological effect is expected as agonists and antagonists were shown
to promote a similar BRET change (Ayoub et al., 2002), no change
(Terrillon et al., 2003), or even different BRET changes on same
BRET assays (Elster et al., 2007), fully disrupting the correlation
between the monitored signal and the expected biological effect.
Therefore, in PPI modulators BRET screening assays, if a known
biological inducing control molecule is available, efforts would be
focused on the design of a BRET assay able to monitor signal
changes in presence of this compound. Nevertheless, compound
promoting an opposite BRET change than the control used might
represent another acting mechanism that could lead to a biological
effect also.
To verify the feasibility of such a BRET approach to screen
for P2I2 in mammal cells, we performed a miniscreens of 320
compounds using both our two PPI screening assays. As seen on
Figure 4B, compounds were able to lower the BRET signal but also
to increase it. Interestingly, some compounds were active on one
assay but not the other. As expected, the total fluorescence reading
(Figure 4C) showed that some compounds promoted changes in
the overall fluorescence properties of the reading buffer in some
wells. However, increased fluorescence was mild compared to those
gained by Fluorescein but leading to no change in BRET signal
(>10 and >2-fold increase respectively for OBRc/OBRGRP and
CD4/PLSCR1; not shown). This indicates that these modifications
prone to BRET signal increase might be of minor importance
when performing P2I2 BRET-based screening assays, depending
on the compound concentration used. On the contrary, BRET sig-
nal decrease, promoted by colored compounds might be more of
concern as the decrease seen in the prescreen reached 50% of basal
fluorescence, a change that promoted high BRET decrease when
studying red phenol containing medium promoted BRET change
(Figure 3G).
CONCLUSION
Bioluminescence resonance energy transfer technique is well
suited to set up high throughput P2I2 screening assays. It has sev-
eral advantages over other methods: it is homogenous; it can be
performed in live cells like FRET but with higher sensitivity; and
allows the monitoring of the studied interactions in a whole intact
cellular context. However, general guidelines have to be respected
when setting up such assays. As in any BRET interaction moni-
toring, the specificity of this interaction has to be checked using
classical DSA. Stable cells lines would be selected in order to assume
ease and reproducibility of the assay and expression of the donor
would be inducible to allow compound to inhibit the target inter-
action before it happens. Kinetic of the induction and interaction
have then to be determined. The kinetic of the BRET signal read-
ing and influence of substrate concentration has to be checked in
order to choose the parameters leading to the best dynamic BRET
output and highest Z ′ factor value for the developed assay. Despite
the fact that only one example of such a successful P2I2 screen-
ing assay (perfomed in yeast) has been published so far, this is a
promising method to develop such assays in mammalian cells. One
huge advantage of P2I2 BRET-based assay compared to classical
methods is its ability to detect not only P2I2 but also conforma-
tional modulators of PPI, also able to promote the final biological
targeted effect. A higher hit rate is then expected when using P2I2
BRET-based assays rather than with classical assays, only able to
detect P2I2. Taken into account this huge advantage over other
PPI monitoring techniques, its important optimization from the
last years, and the still growing data of PPI leading to new poten-
tial drug target selection, a booming use of BRET to develop P2I2
assays would be expected in future years.
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APPENDIX
ENGINEERING OF OBRc/OBRGRP AND CD4/PLSCR1 INDUCIBLE BRET-BASED SCREENING ASSAYS
Fusion protein expression vector cloning
Leptin receptor c isoform (OB-Rc) and phospholipide scramblase 1 (PLSCR1) were cloned in phase with Rluc8 coding sequence in
pcDNA5 vector to gain pcDNA5-OBR-Rluc8 and pcDNA5-Rluc8-PLSCR1 fusion protein expressing vectors. Transcript Leptin receptor
overlapping transcript 1 (OB-RGRP) and CD4 were cloned in pcDNA3 vector in phase with YPet.
Control and BRET cell lines engineering
Rluc8 fusion vectors were transfected in CHO-Trex (invitrogen) cell lines expressing a TetR and blasticidin antibiotic selection allowed
to select resistant clones expressing luciferase activity. In both these BRET control cell line expressing the donor alone, the respec-
tive YPet-tagged partner was transfected and resistant clones selected using further G418 antibiotic selection to obtain BRET cell
lines. OBRc-Rluc8/OBRGRP and CD4/PLSCR1 BRET cell line expressing the highest BRET signal upon stimulation by doxycyclin at
0.1µg/ml for 24 h were selected. The use of the respective corresponding control cell lines allows to monitor BRET background to
calculate mBRET from BRET cell lines.
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